AETMIS considers that, given the modest effectiveness of this therapeutic treatment compared with placebo, its relatively high cost and the additional professional health resources required to administer it, it is not currently justifi ed to contemplate public funding for viscosupplementation for patients with knee OA in Quebec.
However, this treatment could be offered to some people, who would meet strict eligibility criteria similar to those adopted by other third-party payers presented in this report.